A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Amcasertib (Primary) ; Napabucasin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 30 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.